Introduction {#S0001}
============

Acute myeloid leukemia (AML) is a group of hematopoietic disorders marked by arrested differentiation and uncontrolled proliferation of myeloid cells.^[1](#CIT0001)^ Despite our improved understanding of the mechanism of leukemogenesis and advances in therapeutic strategies, the clinical outcome of AML remains generally unsatisfactory.

Current prognostic schemes in AML are largely based on karyotypic information;^[2](#CIT0002)^ for patients without cytogenetic abnormalities, molecular genetic alterations have been shown to predict outcome, with the *NPM1* mutations and biallelic *CEBPA* mutations already incorporated as distinct entities in the current World Health Organization classification of AML.^[3](#CIT0003)^ An increasing number of transcriptomic and epigenomic signatures have also been associated with prognosis in AML.^[4](#CIT0004)--[6](#CIT0006)^ Most of these predictive markers, however, remain investigational. To develop clinically practicable markers, the findings must be properly validated, or, results from independent studies could be integrated using a meta-analysis.

The malignant phenotypes of cancer are contributed not only by tumor-intrinsic alterations but also by the cellular environment around it, especially the immune cells.^[7](#CIT0007)^ This could be demonstrated by the remarkable efficacy of immune checkpoint inhibitors in treating multiple cancers,^[8](#CIT0008),[9](#CIT0009)^ in which the anti-tumor immunity was enhanced by blocking immune checkpoints like *CTLA-4, PD-1*, and *PD-L1*.^[10](#CIT0010)^ Another type of evidence is the prognostic relevance of tumor-infiltrating leukocytes (TILs) in cancers.^[11](#CIT0011)^ For example, the presence of cytotoxic CD8 + T cells is known as an indicator of good prognosis in colorectal, ovarian, and esophageal cancer; whereas a high proportion of immunosuppressive cells, such as regulatory T-cells (Treg), M2-polarized tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs), is reported to predict worse outcome in several cancer types.^[11](#CIT0011)^ Nevertheless, hampered by methodological barriers, these studies can only deal with few cell types or limited samples sizes. Recent progress in computational methods has prompted the investigation of diverse TIL subpopulations simultaneously using large-scale genomic data,^[12](#CIT0012)^ providing us with a more comprehensive view of the clinical implications of TILs and also some novel insights into tumor--immune cell interactions. However, most of these studies have been performed on solid tumors, leaving the role of TILs in hematological malignancies largely unknown.

Indeed, the immunologic microenvironment of hematological malignancies is quite distinctive. As for AML, it initiates and progresses in bone marrow (BM) where most immune cells develop and reside, thus compromising the anti-leukemia immunity and making it a poorly immunogenic cancer. Also, AML is highly immunosuppressive. For example, the frequency of Tregs is significantly higher in AML compared to healthy controls,^[13](#CIT0013)^ and elevated immunosuppressive factors, like indoleamine 2,3-dioxygenase 1 (*IDO1*), is often observed in AML and closely associated with a poor outcome.^[14](#CIT0014)^ Recently, a gene expression-based deconvolution algorithm, CIBERSORT, has been used to investigate the immune infiltration status in a pan-cancer analysis and revealed remarkable differences in immune cell composition between hematopoietic and solid tumors.^[15](#CIT0015)^ However, no study has thus far evaluated the differential composition of multiple TILs between AML and normal specimens, or even other hematological malignancies. In this study, we attempted to address this gap by applying CIBERSORT to a relatively large cohort including five major hematological malignancies and healthy controls. We found that M2 macrophages fractions were increased significantly in AML compared with normal controls. We have also shown that M2 macrophage infiltration could be reflected by *CD206* expression in AML. *CD206*, also known as mannose receptor C type 1 (*MRC1*), is a cell-surface protein abundantly presents on selected populations of macrophages and dendritic cells.^[16](#CIT0016)^ As for macrophages, *CD206* is normally expressed on the M2 but not M1 subtype and therefore serves as a useful marker to identify the M2 phenotype. In a recent study, Mussai et al^[17](#CIT0017)^ reported that *CD206* expression was significantly increased on M2-like monocytes induced by AML blasts and reduced when this phenotype was inhibited. In this study, we have found that *CD206* expression is significantly up-regulated in AML compared to healthy controls, and that high *CD206* expression confers an adverse prognostic influence in AML patients. We believe that *CD206* could serve as a clinically useful biomarker if prospectively validated.

Materials and methods {#S0002}
=====================

Patient samples and data sets {#S0002-S2001}
-----------------------------

All data sets used in this study are publicly available: microarray and RNA-seq gene-expression (GE) data were retrieved from Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) and The Cancer Genome Atlas (TCGA, <https://cancergenome.nih.gov/>), respectively. The detailed information of each data set regarding platforms and sample sizes are summarized in Supplementary Data 1. For Affymetrix microarray data, raw CEL files were normalized with the gcRMA algorithm (GeneSpring GX software, Agilent) and subsequently log2 transformed. For cDNA microarray data (GSE425), where raw GE data was not available, we employed the normalized matrix file instead. Genes with multiple probes were represented by the probe with the highest average GE in each data set.

Three independent data sets were used to estimate the immune cellular fraction (GSE13159, GSE10358, and GSE6891; hereafter referred to as Cohort 1, Cohort 2, and Cohort 3), in which the latter two cohorts were available for clinical outcome information. Cohort 1 consisted of 2096 patients enrolled in the MILE (Microarray Innovations in LEukemia) study,^[18](#CIT0018)^ encompassing five major types of hematological malignancies, that is, acute myeloid leukemia (AML, n = 542), acute lymphoblastic leukemia (ALL, n = 750), chronic myeloid leukemia (CML, n = 76), chronic lymphocytic leukemia (CLL, n = 448), and myelodysplastic syndrome (MDS, n = 206); it also includes normal bone marrow samples (NBM, n = 74) as healthy controls. Cohort 2 consisted of samples from 304 de novo AML patients (269 cases with outcome data) treated per the NCCN guidelines ([www.nccn.org](http://www.nccn.org)); this is also part of the TCGA study of AML.^[19](#CIT0019)^ Cohort 3 comprised of 460 adult AML patients (293 cases with outcome data) treated according to the protocols of the Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON) (available at <http://www.hovon.nl>).^[20](#CIT0020),[21](#CIT0021)^ For these two cohorts, survival information was obtained from the corresponding study or research group, respectively. Both cohorts were available for clinical end points including overall survival (OS) and event-free survival (EFS), which distributed similarly between the two cohorts (Cohort 2, median OS 19.7 months, median EFS, 11.6 months; Cohort 3, median OS 20.5 months, median EFS, 10.9 months).

In a meta-analysis evaluating the predictive value of *CD206*, we further collected 4 datasets containing survival information from public repositories (GSE37642, GSE425, GSE12417, and TCGA RNA-Seq). The GSE37642 and GSE12417 datasets both include two independent patient cohorts, which were profiled on the Affymetrix U133 Plus 2.0 (cohort 1) and U133A platforms (cohort 2), respectively. To calculate the meta-estimates for OS in AML patients with mixed cytogenetic subtypes, five datasets (GSE10358, GSE6891, GSE37642, GSE425, and TCGA RNA-Seq) were used. Except for GSE37642 (whose cytogenetic information was missing), CN-AML subsets from GSE10358 (n = 113), GSE6891 (n = 129), GSE425 (n = 45) and TCGA RNA-Seq data (n = 80), along with GSE12417 comprising exclusively CN-AML cases (cohort 1, n = 79; cohort 2, n = 163), were used to assess the predict performance of *CD206* in CN-AML cohorts. Meta-analysis concerning EFS was based on three datasets with available EFS data (GSE10358, GSE6891, and TCGA RNA-Seq).

Estimation of immune cell fractions {#S0002-S2002}
-----------------------------------

Relative immune cell fractions were estimated using the CIBERSORT algorithm,^[22](#CIT0022)^ based on a reference expression signature containing 547 genes (LM22) that distinguish 22 immune cell subtypes. Briefly, normalized gene expression data were uploaded to the CIBERSORT web portal (<http://cibersort.stanford.edu/>), with the data matrices prepared according to the example mixtures file. Then, CIBERSORT algorithm was running using the default LM22 signature matrix at 1000 permutations. After running, only samples with CIBERSORT *p*-values \< 0.05 were included in subsequent analyses. To display the overall distribution of TIL subtypes among hematological malignancies and controls, mean TIL fractions across samples of each disease type were calculated and depicted as stacked bar charts. Student's t-tests were applied to identify TIL subpopulations that were differentially enriched between AML and controls, controlling for the false discovery rate (FDR) by the Benjamini--Hochberg method (FDR \< 0.05). Association between TIL subsets was done using Pearson correlation and the resulting correlation matrices were visualized using the corrplot R package. Subsequently, univariable Cox regression analysis was performed to evaluate the association between TIL proportions and survival in AML patients, with relative proportions of each cell type tested as continuous variables.

The key findings from CIBERSORT analyses were also validated by xCell (<http://xCell.ucsf.edu/>), a novel method for TIL enumeration that was rigorously developed.^[23](#CIT0023)^ xCell is implemented using a single sample gene set enrichment analysis (ssGSEA) algorithm, which allows calculating the enrichment scores for 64 immune and stromal cell types from gene expression profiles.

Recalculation of the LI24 and LSC17 score {#S0002-S2003}
-----------------------------------------

The LI24 score, originally developed by Li et al.^[24](#CIT0024)^, composed of 24 genes that were derived from a meta-analysis of Cox-regression values of OS from four training sets. While the LSC17 score comprising 17 "stemness" signature genes were developed from a training cohort and highly prognostic in multiple cohorts.^[25](#CIT0025)^ To recalculate the LI24 score, probe sets of the 24 genes were obtained from the two datasets (GSE10358 and GSE6891) (Cohort 2 and Cohort 3). In the case of genes with multiple probe sets, the average expression value for a given gene was used. For genes in the LSC17 score, probe set with the highest mean expression was selected to represent each gene. To generate the LI24 and LSC17 score, log-transformed expression value of the 24 genes and log2-transformed plus scaled expression value of the 17 genes were weighted by their published regression coefficients, respectively. Finally, a median risk score was used to divide patients into high- and low-risk groups.

Statistical analysis {#S0002-S2004}
--------------------

All statistical analyses were performed using the R software version 3.5.3 (<https://www.r-project.org/>). For comparison of two continuous variables, the data were presented as either violin plots or boxplots using the ggplot2 package, with significance determined by Wilcoxon rank sum test. Chi-square test and Fisher's exact test were used to evaluate the association between two categorical variables. Spearman correlation analysis was performed to determine the association between continuous gene expression levels. For survival analyses, patients were divided into high and low *CD206* expressers, based on median *CD206* expression levels. Kaplan--Meier survival curves were generated using the survminer package and compared between groups using a log-rank test. Multivariate Cox regression was employed to test whether high *CD206* expression has independent prognostic value in AML.

The predictive performances of *CD206* and other five prognosticators (*BAALC, ERG, EVI1, MN1*, and *WT1*) were assessed using the Harrell's concordance index (C-index).^[26](#CIT0026)^ The C-index measures the agreement between observed and predicted survival, with a value of 0.5 indicating random prediction and 1 for perfect prediction. With the Cox regression models, we calculated the C-indices, hazard ratios (HRs), and *p*-values of the six genes in each dataset separately. Then, the respective estimates were combined across datasets according to survival endpoints (OS or EFS) and patient groups (cytogenetically heterogeneous AML patients or CN-AML patients). The C-indices and HRs were plotted with lower and upper 95% confidence interval (CI) as forest plots. All these analyses were performed using the R package survcomp. To identify gene signatures associated with *CD206* expression, we performed differential gene expression analysis between high and low *CD206* expressers using the limma package. All statistical analyses were two-sided and a *p*-value less than 0.5 were considered significant.

Results {#S0003}
=======

Differential composition of TIL subpopulations in hematologic malignancies {#S0003-S2001}
--------------------------------------------------------------------------

Using CIBERSORT, we calculated the relative abundance of 22 immune cells in a dataset including 536 AML, 206 MDS, 76 CML, 74 NBM, 749 ALL, and 448 CLL samples.^[18](#CIT0018)^ As shown in [Figure 1a](#F0001), myeloid malignancies (AML, MDS, and CML) were generally dominated by myeloid cells like monocytes, whereas lymphocytes such as B and T cells were found more often in lymphoid leukemia (ALL and CLL). Specifically, neutrophils were preferentially enriched in CML; while in CLL, more than half of total immune cells were B cells. These observations indicate that CIBERSORT can faithfully reflect the cell of origin of human hematologic malignancies. Correlation analysis revealed that proportions of different TIL subsets were weakly to moderately related in AML ([Figure 1c](#F0001)), NBM and other malignancies (Supplementary Figures S1-5), implying the ability of CIBERSORT to robustly discriminate TIL subpopulations in BM samples.10.1080/2162402X.2019.1683347-F0001Figure 1.**Differential composition of TIL subpopulations in hematologic malignancies**. (a) Relative TIL fractions in the BMs of AML (n = 536), MDS (n = 206), CML (n = 76), NBM (n = 74), ALL (n = 749), and CLL (n = 448), as estimated from gene-expression data (GSE13159) using CIBERSORT. CIBERSORT results are represented as mean TIL fractions across samples for each disease type. (b) Heat map showing TIL subpopulations that were differentially infiltrated (FDR \< 0.05) between AML and healthy controls. *p*-values were calculated by Student's t-tests and adjusted for multiple testing (FDR). Side bar on the left denote immune cell types as indicated in (a). (c) Correlation matrix of all 22 immune cell proportions in AML patients from Cohort 1. Variables have been ordered according to the correlation coefficient using hierarchical clustering. (d and e) Violin plots showing the abundance of M2 (up panel) and M0 macrophages (bottom panel) in AML (n = 536) and controls (n = 74), as estimated by CIBERSORT (d) or xCell (e). Boxplots within violin plots show the median and interquartile range of the data distribution. The *p*-values calculated from Wilcoxon test are shown.

By focusing our analysis on AML, strikingly, we observed a significant enrichment of M2 macrophages (0--49%, median: 2%, in AML, vs 0-2%, median: 0%, in NBM, *P* \< .0001) and a concomitant depletion of M0 macrophages (0--12%, median: 0%, in AML, vs 0--15%, median: 6%, in NBM, *P* \< .0001) in AML, as compared to normal BM samples ([Figure 1a,b, and d](#F0001)). Similar results were found when the immune fractions were calculated by xCell (M2 macrophages, 0--31%, median: 9%, in AML, vs 0--8%, median: 1%, in NBM, *P* \< .0001; M0 macrophages, 0--29%, median: 6%, in AML, vs 0--21%, median: 13%, in NBM, *P* \< .0001) ([Figure 1e](#F0001)). Importantly, the preferential enrichment of M2 macrophages in AML was also observed in another two AML cohorts (Cohort 2 and Cohort 3) (Supplementary Figures S6). We then compare TIL subtype fractions between AML and the other four hematological malignancies. Notably, M2 macrophage frequency was consistently higher in AML for all comparisons (Supplementary Figure S7). These observations might be explained by a previous report that AML blasts can act as an inducer of M2 polarization,^[17](#CIT0017)^ therefore leading to increased M2 macrophages from an unpolarized (M0) state. We also observed that AML was highly infiltrated by mast cells, which, like M2 macrophages, often exhibits tumor-promoting activities.^[27](#CIT0027)^ Moreover, the fraction of memory B cells, resting memory T cells, and activated NK cells was higher in AML than in NBM, while tumor-suppressive components like activated memory T cells, activated dendritic cells, and CD8 T cells were decreased in AML ([Figure 1b](#F0001)). Detailed results of these differential analyses were provided in Supplementary Data 2. Overall, these findings were indicative of an immunosuppressive microenvironment in AML relative to healthy BM, consistent with previous observations.^[17](#CIT0017)^

Prognostic implication of TIL subpopulations in AML {#S0003-S2002}
---------------------------------------------------

Next, we asked whether these immune components predict outcome in AML, as they have been reported in solid tumors.^[11](#CIT0011)^ To this end, we applied CIBERSORT to two AML datasets with survival information (Cohort 2 and Cohort 3). After filtering samples with CIBERSORT *p*-values less than 0.05, the estimated proportions of 22 cell subsets as continuous variables were correlated to the patients' outcome. Although we observed no consistent prognostic significance of individual cell types between two cohorts, we did note that, in Cohort 2, M2 macrophages represented a significant negative predictor of clinical outcome (OS, *P* \< .001, EFS, *P* = .019; [Figure 2a](#F0002)); while in cohort 3, M1 macrophages emerged as the only significant predictor for prolonged survival (OS, *P* = .027; EFS, *P* = .01; Supplementary Figure S8). These observations, albeit without mutual validation, were largely consistent with those documented in solid tumors.^[28](#CIT0028)^ Importantly, for M2 macrophages, the results remained significant when the cellular proportions were modeled as quartiles using log-rank test, or, estimated by xCell ([Figure 2b](#F0002)). As for other cell types in Cohort 2, a higher fraction of activated mast cells, T follicular helper cells (Tfh cells), and resting mast cells was associated with both improved OS and EFS, whereas more infiltration of monocytes was correlated with both worse OS and EFS ([Figure 2a](#F0002)). In Cohort 3, increased infiltration of Tregs and Tfh cells showed similar degrees of shorter survival (Supplementary Figure S8).10.1080/2162402X.2019.1683347-F0002Figure 2.**Prognostic associations of TIL subpopulations in AML**. (a) Forest plots showing the associations of continuous TIL concentrations with overall survival (OS, left) and event-free survival (EFS, right) in Cohort 2. The hazard ratios (HRs) were plotted with lower and upper 95% confidence intervals (CI) in the forest plots. *p*-values were obtained from a univariate Cox regression analysis. (b) OS and EFS in AML patients (Cohort 2) defined by quartiles (Q1-Q4) of M2 macrophage abundances. The relative abundances of M2 macrophages were estimated by CIBERSORT (left panel) and xCell (right panel), respectively. Depicted *p*-values were calculated from log-rank tests.

For all the immune cells analyzed, we considered M2 macrophages as the one who merits further investigation: it was previously shown to be induced by AML blasts; our results accordingly demonstrated its preferential enrichment and adverse prognostic impact in AML. Moreover, these results remained significant when M2 infiltration levels were estimated by xCELL ([Figures 1e](#F0001) and [2b](#F0002)).

CD206 expression reflects variation in M2 macrophage abundance and is up-regulated in AML patients {#S0003-S2003}
--------------------------------------------------------------------------------------------------

The above results have shed some light on the dysregulation of M2 macrophages in AML. We therefore further asked whether M2 macrophages marker genes were similarly altered in AML. Based on the published literature,^[29](#CIT0029)^ we selected *CD68, CD163, CD204*, and *CD206* as surrogate markers for M2 macrophages. First, AML patients in three cohorts were dichotomized at the median of M2 infiltrating levels, mRNA expressions of the four genes were then compared between patients with high and those with low M2 infiltration. As shown in [Figure 3a](#F0003), only *CD206* was able to accurately reflect the abundances of M2 macrophages in all AML cohorts, as compared to the other three markers. This finding is consistent with a previous study showing that *CD206* was significantly up-regulated on induced M2-like cells in AML patients.^[17](#CIT0017)^ In addition, we compared *CD206* expression between high and low levels of dendritic cells (resting and activated), since *CD206* could also be expressed on certain dendritic cell subpopulations.^[16](#CIT0016)^ Significant association was observed with resting dendritic cells, but not with activated dendritic cells for all comparisons (Supplementary Figure S9). We also examined the association between *CD206* the three macrophage markers. *CD206* expression showed significant and positive correlations with the expression levels of *CD68, CD163*, and *CD204* in all the three datasets (Supplementary Figure S10). The strongest correlation was found between *CD206* and *CD163*, a marker routinely used to identify the M2 phenotype. Although we cannot rule out the presence of *CD206* on dendritic cells, our analysis nonetheless supports *CD206* as a potentially valid marker for M2 macrophages in AML.10.1080/2162402X.2019.1683347-F0003Figure 3.***CD206* expression reflects variation in M2 macrophage abundance and is more highly expressed in AML patients than normal controls**. (a) mRNA levels of M2 marker genes (*CD68, CD163, CD206*, and *CD204*) between patients with high (above median) and low (below median) M2 macrophage abundances in three AML cohorts. Data are presented as median and IQR. The *p*-value from Wilcoxon test is shown. (b) Boxplots showing *CD206* expression in AML and normal controls using GEPIA (<http://gepia.cancer-pku.cn/detail.php?gene=&clicktag=boxplot>) and two published datasets (GSE24006 and GSE63270). (c) Dot chart comparing the expression levels of *CD206* in sorted monocyte-like cells from AMLs (n = 2385) and monocytes from normal BM (n = 567), as assessed by single-cell RNA-sequencing (van Galen P et al., 2019).

The next question was whether *CD206* was up-regulated in AML as M2 macrophages did. Using the bioinformatics tool GEPIA (<http://gepia.cancer-pku.cn/detail.php?gene=&clicktag=boxplot>) and two published datasets (GSE24006 and GSE63270), we found remarkably higher expression of *CD206* in AML patients than normal controls ([Figure 3B](#F0003)). Furthermore, the up-regulation of *CD206* was also observed in sorted malignant monocyte-like cells from AML patients compared to their normal counterparts ([Figure 3c](#F0003)), as demonstrated by a recently published single-cell RNA-seq data.^[30](#CIT0030)^ These data together suggest that *CD206* expression is commonly altered in AML and could be indicative of the status of M2 macrophages.

Prognostic impact of high CD206 expression in AML {#S0003-S2004}
-------------------------------------------------

Next, we examined the prognostic effect of the four genes in Cohort 2 (n = 269). Remarkably, we found that 3 of the 4 genes -- *CD68, CD163*, and *CD206* -- whose increased expression levels were significantly associated with worse OS (*P* = .009, *P* = .023, and *P* = .001, respectively; Supplementary Figure S11A); though for EFS only *CD206* showed a trend toward significance (*P* = .058, Supplementary Figure S11B). Restricting analyses to AML patients with a normal karyotype (CN-AML), however, *CD206* emerged as the only significant predictor both for OS (*P* = .011) and EFS (*P* = .005) ([Figure 4a](#F0004)). We also tested the prognostic value of these genes in a validation cohort (Cohort 3, n = 293). While increased expression of *CD68, CD163*, and *CD204* have failed to show any association with survival in this cohort (Supplementary Figure S11B), high *CD206* levels were again significantly associated with shorter OS (*P* \< .001) and EFS (*P* = .001) (Supplementary Figure S11B). Similar results were observed in AML cases with a normal karyotype (CN-AML cases) ([Figure 4b](#F0004)). Overall, these analyses allowed us to validate *CD206* as a strong prognosticator both in the full cohort as well as in the CN-AML subset.10.1080/2162402X.2019.1683347-F0004Figure 4.**Identification of *CD206* as a predictor of outcome in AML.** (a and **b)** OS and EFS analyses based on mRNA expression levels of the four M2 marker genes (*CD68, CD163, CD206*, and *CD204*) in CN-AML patients from Cohort 2 (a) and Cohort 3 (b). Patients were stratified in two groups using the median expression value as a cutoff. The *p*-values were computed using log-rank tests.

Finally, multivariate analyses were performed for these two cohorts. In a multivariate model for Cohort 2, high *CD206* expression independently predicted poor OS (*P* = .001) after adjusting for age and *NPM1* status, and poor EFS (*P* = .02) after adjusting for age, *FLT3*-ITD, and *NPM1* status (Supplementary Table S1). In Cohort 3, patients with high *CD206* expression had a shorter OS (*P* = .03) and a trend for shorter EFS (*P* = .06) when controlling for *FLT3*-ITD, *NPM1*, and CEBPA mutation status, and cytogenetic risk group (Supplementary Table S1). Among CN-AML patients, *CD206* remained an independent predictor of shorter OS and EFS for both cohorts ([Table 1](#T0001)). Next, we tested if mutations such as *TP53, DNMT3A, TET2, RUNX1, IDH1*/*2, ASXL1*, and *NRAS* affected the prognostic impact of *CD206* expression in the TCGA cohort, since extensive mutational profiling data was available only for this cohort. The previously described molecular mutations and *CD206* expression as well as common clinical parameters (age, WBC count, cytogenetic risk group) were first analyzed in a univariate analysis (data not shown). Variables with a *p*-value less than 0.2 were further included in a multivariate model for OS and EFS, respectively. In the whole cohort, high *CD206* expression independently predicted worse EFS (*P* = .04) when controlling for WBC count (*P* = .008) (Supplementary Table S2). However, it was not independently associated with OS after adjusting for other covariates (*P* = .27) (Supplementary Table S2). Moreover, the independent prognostic value of *CD206* for OS and EFS was lost in the CN-AML subsets (OS, *P* = .14; EFS, *P* = .11) (Supplementary Table S2). Larger prospective studies should, however, be investigated to evaluate these results.10.1080/2162402X.2019.1683347-T0001Table 1.Multivariate analysis of *CD206* expression for overall survival and event-free survival in CN-AML subsets of the two independent cohorts. Overall survivalEvent-free survivalVariablesHazard Ratio (95% CI)*P*Hazard Ratio (95% CI)*P***Cohort 2(n = 113)(n = 113)***CD206*^a^1.58 (1.08--2.32)0.021.56 (1.03--2.37)0.04Age^b^1.04 (1.03--1.06)\< 0.0001\--*FLT3-ITD*^c^1.66 (1.06--2.62)0.031.40 (0.86--2.28)0.18**Cohort 3(n = 129)(n = 129)***CD206*^a^1.56 (1.14--2.13)0.0051.49 (1.11--2.00)0.008*FLT3-ITD*^c^1.46 (1.05--2.02)0.021.32 (0.96--1.81)0.08[^1][^2][^3][^4][^5]

Additional value of CD206 expression in refining risk stratification in AML {#S0003-S2005}
---------------------------------------------------------------------------

The prominent prognostic role of *CD206* status led us to hypothesize that it may add prognostic value to the established prognostication systems. To date, cytogenetics remains as the mainstay for risk assessment in AML patients; however, for those assessed as intermediate risk, survival outcomes and treatment responses differed substantially. We thus tested the prognostic value of *CD206* in this heterogeneous group of AML patients. In Cohort 3, 60% (175/293) of patients were classified as intermediate risk based on cytogenetic information. Using *CD206* status as the classifier, this group could be further dichotomized into two groups with remarkably different outcomes: The favorable group had a 3-year OS of 56% and a 3-year EFS of 47%, with median OS not reached and a median EFS of 25.7 months; while the unfavorable group only had a 3-year OS of 32% and a 3-year EFS of 25%, with a median OS of 13 months and a median EFS of 8.4 months (*P* \< .0001 for OS and *P* \< .001 for EFS; [Figure 5a](#F0005)).10.1080/2162402X.2019.1683347-F0005Figure 5.**Prognostic value of *CD206* expression in the context of established risk stratification schemes.** (a) OS and EFS according to *CD206* expression levels among intermediate-risk patients from Cohort 3. (b) OS of CN-AML patients (Cohort 3) in the ELN Favorable (left) and ELN Intermediate-I (right) genetic groups, according to *CD206* expression levels. (c and d) OS and EFS of patients from Cohort 2 (left) and from Cohort 3 (right) as stratified by the LI24 (c) and the LSC17 (d) signature. Patients with a low and high risk score were further dichotomized according to *CD206* expression levels.

The European Leukemia Net (ELN) risk scheme complements cytogenetics by further stratifying CN-AML patients into two risk groups: ELN Favorable and ELN Intermediate-I.^[31](#CIT0031)^ For the two cohorts analyzed, only CN-AML cases from Cohort 3 can be subdivided using this scheme (OS; *P* = .008; EFS; *P* = .012; Supplementary Figure S12A). Indeed, for OS, high *CD206* expression even identified a small number of high-risk patients within the ELN Favorable group (median OS 17.1 months, 3-year OS 36% versus median OS not reached, 3-year OS 63% for patients with high and low *CD206* expression, respectively; *P* = .045; [Figure 5b](#F0005)). In the ELN Intermediate-I category, however, *CD206* lost its prognostic impact (*P* = .36, [Figure 5b](#F0005)). For EFS, *CD206* expression status was no longer significant in predicting patient outcome, both in the ELN Favorable and Intermediate-I categories (Supplementary Figure S12B).

Several gene expression-based prognostic models have been proposed recently. Two of them-LI24 and LSC17-have demonstrated their superior prognostic performance and ability to improve risk stratification for AML patients.^[24](#CIT0024),[25](#CIT0025)^ It is therefore also interesting to test the predictive power of *CD206* expression in the context of these novel schemes. We generated both models in our two cohorts and patients were stratified into high- and low-risk groups accordingly ([Figure 5C,D](#F0005)). When applied to each risk group stratified by LI24, *CD206* expression remained a significant predictor for OS and EFS in most instances, either within high- or low-risk groups ([Figure 5C](#F0005)). For subgroups divided by LSC17, *CD206* status appears to dichotomize survival only in the high-risk group ([Figure 5D](#F0005)). In summary, these results suggest *CD206* as a good candidate for refining existing classification schemes.

Association between CD206 expression and treatment response {#S0003-S2006}
-----------------------------------------------------------

Good biomarkers are useful not only in facilitating risk assessment, but also in guiding therapeutic decisions. The recently published Beat AML dataset is the largest study to date that investigates the association between genetic data (whole-exome and RNA sequencing) and drug sensitivity in AML. In this cohort (n = 562), 411 patients were available for both gene expression and clinical data. Among the 320 patients underwent standard chemotherapy, 184 (57.5%) patients achieved a complete response (CR), 105 (32.8%) patients showed a refractory disease, and 31 (9.7%) patients has no available therapy response information. The whole cohort (n = 411) were first divided into two groups based on the median expression value of *CD206*. Patients with higher *CD206* expression had a lower response rate to induction chemotherapy, with a CR rate of 56.9% versus 70.3% for patients with lower *CD206* expression (*P* = .018). Additionally, *CD206* expression in CR specimens (n = 203) was significantly lower than refractory specimens (n = 116) (*P* = .041, [Figure 6a](#F0006)).10.1080/2162402X.2019.1683347-F0006Figure 6.**Association between *CD206* expression and treatment response.** (a) Boxplot showing *CD206* expression in samples from patients achieving a complete response (n = 203) and patients showing a refractory disease (n = 116) in the Beat AML cohort. The *p*-value from Wilcoxon test is shown. (b and c) Kaplan--Meier curves of OS and EFS for patients with high (b) or low (c) *CD206* expression as stratified by treatment options (alloSCT versus no alloSCT) in the TCGA cohort. alloSCT, allogeneic stem cell transplantation.

Allogeneic stem cell transplantation (alloSCT), an intensive therapeutic strategy, is often performed on high-risk patients due to treatment-associated modalities. To explore the impact of alloSCT according to *CD206* status, subgroup analysis was performed on 183 patients with treatment information (TCGA cohort), as stratified by donor status. Among patients with high *CD206* expression, OS was significantly improved for the donor group (median OS 26.3 months, 3-year OS 40%) compared with the no-donor group (median OS 6 months, 3-year OS 22%; *P* = .002; [Figure 6b](#F0006)); but this benefit no longer retained for EFS (*P* = .38; [Figure 6b](#F0006)). In patients with low *CD206* expression, the outcome was not significantly influenced by transplantation (OS, *P* = .10; EFS, *P* = .11, [Figure 6c](#F0006)).

Predictive performance of CD206 compared with other established prognostic markers {#S0003-S2007}
----------------------------------------------------------------------------------

In order to evaluate the clinical utility of *CD206* as well as to compare its predictive performance with other classical gene expression markers (*BAALC, ERG, EVI1, MN1*, and *WT1*), we further collected 4 datasets containing survival information from public repositories; these, together with the previous two datasets, allowed us to perform a meta-analysis of Cox regression estimates of each gene. Gene expression was treated as a continuous variable to ensure statistical robustness, and the performance of each gene was evaluated using Harrell's concordance index (c-index). The estimated c-indexes of each gene were merged across datasets both in the entire AML population (Supplementary Figure S13) and in the CN-AML subsets (Supplementary Figure S14), for OS and EFS, respectively. The overall c-index of each gene was compared, as shown in the forest plots ([Figure 7a,b](#F0007)). In the entire AML population, *CD206* performed significantly better than all the other genes for both OS and EFS ([Figure 7a](#F0007)). In CN-AML patients, the predictive performance of *BAALC, ERG, MN1*, and *WT1* increased slightly but was still outperformed by *CD206* ([Figure 5b](#F0005)). We further computed the hazard ratio and Cox regression *p*-value of each gene across datasets (Supplementary Figures S15 and S16 for all AML cases and CN-AML cases, respectively), followed by a meta-analysis of these estimates ([Figure 7c](#F0007),D for all AML cases and CN-AML cases, respectively). Notably, the predictive power of *CD206* was especially pronounced in CN-AML patients; it exhibited a highly significant association with survival in almost all CN-AML cohorts (Supplementary Figure S16), with an overall *p*-value of 2.44 × 10^−11^ for OS and 1.66 × 10^−7^ for EFS ([Figure 7d](#F0007)). *ERG* appeared as the only other gene that was significantly associated with both OS and EFS in CN-AML patients (*P* = .0003 and *P* = .035, respectively; [Figure 7d](#F0007)). Overall, this multi-cohort meta-analysis demonstrated *CD206* as a robust tool for outcome prediction in AML patients. However, prospective clinical trials will be needed before it can be translated into routine clinical practice.10.1080/2162402X.2019.1683347-F0007Figure 7.**Predictive performance of *CD206* for OS and EFS compared with classical prognostic markers (*BAALC, ERG, EVI1, MN1*, and *WT1*).** (a and b) Forest plot reporting the overall concordance indices for the six genes in all AML cases (a) and CN-AML cases (b). The concordance indices were combined for datasets with OS information (left) and EFS information (right), respectively. (c and d) Forest plot reporting the overall hazard ratios and *p*-values for the six genes in all AML cases (c)and CN-AML cases (d). The hazard ratios and *p*-values were combined for datasets with OS information (left) and EFS information (right), respectively. The *p*-values were computed from Cox regression analysis in each dataset and combined using the weighted Z-method. Results for individual genes in each dataset were provided in Figure S13--16.

Association of CD206 expression with morphologic, cytogenetic and genetic abnormalities {#S0003-S2008}
---------------------------------------------------------------------------------------

We also investigated the relationship of *CD206* expression with morphologic, cytogenetic, and molecular abnormalities in Cohort 2 and Cohort 3. In Cohort 2, high *CD206* expressers more often presented with M0 (*P* = .05) and M4 (*P* = .003) morphologies and less often with M3 (*P* = .0001) ([Table 2](#T0002)). Associations with M4 subtypes could also be confirmed in Cohort 3 (*P* \< .001) ([Table 2](#T0002)). Concerning cytogenetics, high *CD206* expression was nearly exclusively found in patients with inv(16) but less frequently found in t(15;17) cases; this was true for both Cohorts ([Table 2](#T0002)). Since patients from Cohort 2 are also enrolled as part of the TCGA study of AML, and extensively annotated genomic data were available for the TCGA cohort, correlation of mutational data (the top 10 mutated genes) with *CD206* expression was first performed in this cohort. The results show that high *CD206* expression was positively associated with the presence of *TP53* (*P* = .034) and *RUNX1* mutations (*P* = .003), but inversely correlated with *NPM1* (*P* = .049) and *IDH1* mutations (*P* = .023) ([Figure 8a](#F0008)). In Cohort 3, we found that higher *CD206* expressers more frequently harbored *FLT3*-ITD (*P* \< .0001) and *NRAS* (*P* = .041), and less frequently harbored *NPM1* (*P* = .005), *IDH1* (*P* \< .001), and *IDH2* (*P* = .02) mutations ([Figure 8b](#F0008)). Overall, the negative relationships between high *CD206* expression and *NPM1* and *IDH1* mutations were observed in both cohorts.10.1080/2162402X.2019.1683347-T0002Table 2.Association of *CD206* expression with morphologic and chromosomal abnormalities.VariableAML (Cohort 2)High *CD206*\
(n = 150)Low *CD206*\
(n = 150)*P*FAB classification, n (%)    M016 (10.7)7 (4.7)0.05 M128 (18.7)37 (24.7)0.21 M237 (24.7)33 (22.0)0.59 M39 (6.0)32 (21.3)0.0001 M446 (30.7)24 (16.0)0.003 M58 (5.3)15 (10.0)0.13 M62 (1.3)1 (0.7)1 M72 (1.3)1 (0.7)1 Unknown2 (1.3)0 (0)0.50Cytogenetics, n (%)    normal61 (40.9)69 (46.0)0.38 t(8;21)6 (4.0)8 (5.3)0.59 inv(16)20 (13.4)2 (1.3)\< 0.0001 t(15;17)8 (5.4)30 (20)0.0001 Complex15 (10.1)5 (3.3)0.02 AML (Cohort 3)\*VariableHigh *CD206*\
(n = 221)Low *CD206*\
(n = 222)*P*FAB classification, n (%)    M010 (4.5)6 (2.7)0.30 M136 (16.3)59 (26.6)0.008 M247 (21.3)58 (26.1)0.23 M38 (3.6)16 (7.2)0.10 M454 (24.4)25 (11.3)\< 0.001 M4E5 (2.3)0 (0)0.03 M555 (24.9)49 (22.1)0.48 M64 (1.8)2 (0.9)0.45 Unknown2 (0.9)7 (3.2)0.09Cytogenetics, n (%)    normal82 (37.1)99 (44.6)0.11 t(8;21)15 (6.8)20 (8.3)0.39 inv(16)33 (14.9)1 (0.5)\< 0.0001 t(15;17)6 (2.7)15 (6.8)0.05 Complex6 (2.7)7 (3.2)0.78[^6][^7] 10.1080/2162402X.2019.1683347-F0008Figure 8.**Co-mutation plot showing the distribution of gene mutations in AML patients with low and high *CD206* expression.** (a) TCGA Cohort (n = 183); (b) Cohort 3 (n = 460). Each column represents an individual sample. Gray boxes indicate mutation and white boxes indicate wild type. ITD denotes internal tandem duplication.

Gene expression signatures associated with CD206 expression {#S0003-S2009}
-----------------------------------------------------------

To further assess the role of *CD206* in AML, we derived *CD206*-associated gene expression profiles using three independent AML datasets (GSE13159, n = 542; GSE10358, n = 304; and GSE6891, n = 460) (Cohort 1, Cohort 2, and Cohort 3). Probe sets with at least one fold change in "*CD206* high" versus "*CD206* low" patients and an adjusted *p*-value \< 0.05 were identified, and were collapsed into unique genes. The differentially expressed genes from each comparison were intersected, and those existed in at least two gene lists were considered as the core signature (Supplementary Data 3). Among the genes positively correlated with *CD206* expression, many were, like *CD206* itself, established M2 markers, such as *CD163, CD180, CD36, CD93, CLEC10A, MS4A4A, MS4A6A*, and *TGFBI*. Some genes involved with monocyte/macrophage differentiation or migration were also identified, for example, *S100A9, S100A12, MPEG1, MAFB, CCR1, CCR2*, and *SPARC*. Besides, we found genes that were implicated in immune suppression and tumor progression, that is, *CD200, VSIG4*, and *VCAN*. It is important to note that, among these genes, *CD36, S100A9, SPARC* and *CD200* were also reported as adverse prognostic factors in AML,^[32](#CIT0032)--[35](#CIT0035)^ providing further evidence for a pathogenetic link between M2 macrophages and leukemogenesis. Additional predictive markers in AML were found; these include the classical ones like *CD34, BAALC*, and *MN1*,^[36](#CIT0036)--[40](#CIT0040)^ and some newly-identified prognosticators, including *CD52*, *HOPX*, and *VNN1*.^[41](#CIT0041)--[43](#CIT0043)^ Importantly, *CD52* was also known as a promising immunotherapy target in AML.^[44](#CIT0044)^ Few genes were negatively correlated with *CD206* expression (only 6 were consistent in at least two datasets); among them was *CRNDE*, a long non-coding RNA recently reported as being associated with worse outcome in AML.^[45](#CIT0045)^

Discussion {#S0004}
==========

Here, we performed a comprehensive analysis of the overall distribution of 22 TIL subpopulations in more than 2000 BM samples from control and 5 major hematological malignancies. Relative TIL proportions were estimated from gene expression profiles of these samples, using the state-of-the-art computer algorithm, CIBERSORT.^[22](#CIT0022)^ We found that patients with AML exhibit increased frequencies of M2 macrophages compared to either healthy controls or the other four hematological tumors. In line with this, Mussai et al.^[17](#CIT0017)^ have demonstrated that AML blasts can induce polarization of surrounding monocytes into M2-like cells, as indicated by elevated expression of the M2 marker *CD206*. Our findings also underscore the poor prognostic impact of M2 macrophages in AML patients. This observation, largely consistent with the published data in other cancer types,^[28](#CIT0028)^ indicating a tumor-promoting potential of M2 macrophages in AML. In solid tumors, M2 macrophages can not only suppress anti-tumor immune responses but also incite many malignant behaviors of tumor progression, including angiogenesis, invasion, metastasis, and persistent growth.^[46](#CIT0046)^ In AML, however, the pathological role of M2 macrophages is still largely unknown and needs to be elucidated in future studies.

Regarding other TIL subpopulations, Tregs were identified as an adverse prognosticator in Cohort 3, however, no increase of Tregs was seen in AML compared with controls; this is only partially consistent with a previous finding showing that Tregs expand in AML and high infiltration of Treg cells has been correlated with reduced remission rates following standard chemotherapy.^[13](#CIT0013)^ Interestingly, mast cells had higher proportions in AML than in controls, but it seems to be associated with a favorable outcome. The reason for this is difficult to elucidate: while both tumor-promoting and tumor-suppressive roles of mast cells have been described in cancers,^[47](#CIT0047)^ we concluded that mast cells can confer either good or poor prognosis depending on the context.

Although TIL concentrations calculated from CEBERSOT can provide novel prognostic information in AML, their clinical utility should be interpreted with some caveats in mind. First, the TIL frequencies were computationally inferred from microarray data: acquiring genome-wide expression data might be expensive and wasteful in clinical practice when large sample sizes are required. Second, experimental strategies, such as IHC or flow cytometry, are recommended to validate computational discoveries to avoid hasty conclusions. Third, discrepancies exist between patient cohorts regarding the prognostic impact of certain TIL subpopulations; they may be due to between-cohort heterogeneity in genetic background, tumor microenvironment, and treatment regimens-all would exert crucial influences on the individual's immune response and therefore may complicate the prognostic impact of TILs. Overall, future functional immunological data and prospective validation will be required before this in silico approach can be used in a clinical setting.

Next, we sought to determine whether M2 macrophages marker genes would have a similar clinical effect in AML. Among four established markers of M2 macrophages-*CD68, CD163, CD204*, and *CD206*-we found that only *CD206* can truthfully reflect variation in M2 concentrations in AML. This finding supports the previous report that *CD206* was significantly increased on M2-polarized monocytes in AML and reduced when these cells were phenotypically reverted.^[17](#CIT0017)^ Further survival analyses demonstrated *CD206* as a significant adverse predictor both for OS and EFS in AML patients. Our analyses have several strengths: the prognostic value of *CD206* was discovered in two relatively large cohorts; in assessing predictive performance, *CD206* expression was treated as a continuous variable, and the results were integrated from multiple independent cohorts using a meta-analysis, thereby increasing the statistical power of the study and allowing us to evaluate *CD206* expression as a robust predictor for clinical outcome in AML patients. Nevertheless, the retrospective nature and heterogeneity among study populations could be the main limitations of this work. Therefore, prospective randomized studies will be required before *CD206* expression can be translated clinically.

Another important finding relates to the prognostic value of *CD206* expression in the context of well-established classification systems. The ELN classification, for example, stratifies CN-AML patients into two prognostically different subsets of patients, based on three molecular genetic markers.^[31](#CIT0031)^ This scheme, however, is only applicable for CN-AML cases from Cohort 3; we found that ELN Favorable patients within this cohort could be further dichotomized into prognostic subsets based on expression levels of *CD206*, suggesting that *CD206* expression can be useful to refine accepted CN-AML classification scheme.

Despite such strong prognostic implications, the causal relationship between high *CD206* expression and the adverse prognostic impact remains elusive. There are several potential explanations for this observation. First, as demonstrated above, high *CD206* expression might only reflect a preferential enrichment of M2 macrophages. Therefore, it can be hypothesized that part of the prognostic value of *CD206* could be attributed to major underlying differences of the density of infiltrating M2 macrophages. Indeed, *CD206* has been used as a marker for detecting M2 macrophages in hepatocellular carcinoma (HCC) and elevated number of *CD206*+ M2 cells defined a subgroup of patients with inferior survival.^[48](#CIT0048),[49](#CIT0049)^

The adverse prognostic impact of *CD206* might also be explained by the distinct gene expression signatures associated with it. Among them were well-known prognostic markers in AML-*BAALC, MN1*, and *CD34*,^[36](#CIT0036)--[40](#CIT0040)^ and also some newly-identified strong prognosticators like *CD52, HOPX*, and *VNN1*.^[41](#CIT0041)--[43](#CIT0043)^ Importantly, several immunosuppressive factors were found, including *CD200, VSIG4*, and *VCAN*. It is noteworthy that *CD200*, a cell membrane protein like *CD206*, is frequently up-regulated in AML and associated with a poor patient outcome.^[35](#CIT0035)^ Functional studies have shown that the expression of *CD200* on AML blasts could promote Treg formation while suppress the function of NK and memory T-cells.^[50](#CIT0050)--[52](#CIT0052)^ These observations suggest a causal link between immunosuppression and poor clinical outcomes in AML.

However, whether *CD206* is directly implicated in leukemogenesis has not been answered. As previously demonstrated, *CD206* could act as an adhesion molecule during leukocyte trafficking within the lymphatics; it might as well mediate cancer cell metastasis to the local lymph nodes.^[53](#CIT0053)^ Recently, we and others have shown that the dysregulation of cell adhesion proteins was a common feature in AML and had a profound impact on the clinical outcome.^[54](#CIT0054),[55](#CIT0055)^ Thus, it is possible that the pro-metastasis potential of *CD206* might allow leukemia cells to adopt an enhanced invasive capacity and more extensive extramedullary infiltration, finally leading to a worse patient outcome. Despite the evidence discussed above, the role of high *CD206* expression in the leukemogenesis of AML remains to be defined.

In summary, we reported here that BM from AML patients exhibited higher levels of M2 macrophages than controls and patients with high M2 infiltration seem to have a worse prognosis. Furthermore, we described a novel strong prognosticator in AML, the M2 marker *CD206*, who had superior predictive performance than well-established prognostic markers. *CD206* may also be useful in improving existing molecularly based risk classification schemes and in guiding the selection of therapeutic regimens. Future studies should prospectively validate our findings and determine the mechanisms by which high *CD206* adversely impacted survival in AML.
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[^1]: Abbreviations: CN, cytogenetically normal; CI, confidence interval; ITD, internal tandem duplication.

[^2]: NOTE: Hazard Ratio \> 1 or Hazard Ratio \< 1 indicate a higher or lower risk. Only variables with a univariable *p*-value ≤ 0.20 were included in the multivariable models.

[^3]: ^a^High vs low expression.

[^4]: ^b^\> 60 vs ≤ 60 years.

[^5]: ^c^Present vs absent.

[^6]: Abbreviations: AML, acute myeloid leukemia;

[^7]: \*17 cases of myelodysplastic syndrome (MDS) cases are removed from Cohort 3 (n = 460), leaving 443 cases for analysis.
